Introduction: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease that frequently progresses to liver failure, recurrent bacterial cholangitis, and the need for liver transplantation. Because the Model for End-Stage Liver Disease (MELD) score may not fully capture the disease burden experienced by some patients with PSC, exception policies have been developed to provide additional transplant priority in selected circumstances.
Introduction:
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease that frequently progresses to liver failure, recurrent bacterial cholangitis, and the need for liver transplantation. Because the Model for End-Stage Liver Disease (MELD) score may not fully capture the disease burden experienced by some patients with PSC, exception policies have been developed to provide additional transplant priority in selected circumstances. However, the appropriateness and effectiveness of these exceptions remain an area of ongoing debate.
Problem Statement:
MELD exception policies are intended to address clinical situations in which standard MELD scores underestimate transplant urgency. In PSC, exceptions have often been granted for recurrent cholangitis and other disease-related complications, yet the supporting evidence has been limited and inconsistent. Determining whether these policies accurately identify patients with increased mortality risk or improved transplant benefit is essential to maintaining fairness in organ allocation.
Summary:
This editorial examines the current practice of granting MELD exception points for patients with PSC and questions whether existing policies are sufficiently supported by robust clinical evidence. The authors highlight a central challenge in transplant allocation: balancing the need to recognize PSC-specific complications while ensuring equitable organ distribution across all liver disease populations. Although recurrent bacterial cholangitis and related complications can significantly impair quality of life and contribute to morbidity, evidence linking these events to a clearly increased waitlist mortality risk remains limited. The editorial argues that exception policies should be driven by objective data demonstrating measurable transplant benefit rather than historical practice patterns or expert consensus alone. The authors emphasize the need for contemporary outcome-based studies that evaluate waitlist mortality, post-transplant outcomes, and the true impact of PSC-related complications on patient prognosis. As transplant medicine increasingly moves toward evidence-based allocation systems, reassessment of PSC exception policies may be necessary to ensure fairness, transparency, and optimal use of scarce donor organs. The article ultimately calls for stronger data to guide future policy decisions and to determine whether current MELD exception practices for PSC remain justified in modern liver transplantation.
Introduction: IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder that can affect virtually any organ. Although glucocorticoids remain the mainstay of treatment, relapse is common after tapering, and long-term steroid toxicity remains a major concern....
Introduction: Hepatitis B virus (HBV) reactivation remains a potentially serious complication of immunosuppressive and anticancer therapies. While current guidelines classify patients into high-, moderate-, and low-risk categories, this editorial discusses new real-world evidence suggesting that...
Introduction: Liver disease is entering a new era. While steatotic liver disease (SLD) is rapidly becoming one of the world's leading non-communicable diseases, progress toward viral hepatitis elimination has slowed. This editorial highlights the urgent...
Introduction: Therapeutic plasma exchange (TPE) is increasingly used in pediatric acute liver failure (ALF), but it artificially lowers bilirubin and INR, making it difficult to determine whether a child is truly improving or requires urgent...
Introduction: For decades, low-to-moderate alcohol consumption has been considered by some to offer potential cardiovascular benefits. This comprehensive U.S. modeling study re-evaluated the lifetime health impact of alcohol consumption using contemporary cause-specific data on alcohol-related...
Introduction: Advances in genetic sequencing have transformed the understanding of cholestatic liver diseases. Conditions once considered exclusive to children are now recognized in adolescents and adults, with genetic variants increasingly explaining unexplained cholestasis, recurrent pruritus,...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.